CA3003760A1 - Drug for inhibiting adipose cell differentiation and insulin resistance - Google Patents

Drug for inhibiting adipose cell differentiation and insulin resistance Download PDF

Info

Publication number
CA3003760A1
CA3003760A1 CA3003760A CA3003760A CA3003760A1 CA 3003760 A1 CA3003760 A1 CA 3003760A1 CA 3003760 A CA3003760 A CA 3003760A CA 3003760 A CA3003760 A CA 3003760A CA 3003760 A1 CA3003760 A1 CA 3003760A1
Authority
CA
Canada
Prior art keywords
group
mice
fat diet
mes
weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3003760A
Other languages
English (en)
French (fr)
Inventor
Yongzhang Luo
Hui Wang
Hui Li
Xinan Lu
Yan Fu
Shunli ZHAN
Daifu ZHOU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tsinghua University
Protgen Ltd
Original Assignee
Tsinghua University
Protgen Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tsinghua University, Protgen Ltd filed Critical Tsinghua University
Publication of CA3003760A1 publication Critical patent/CA3003760A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CA3003760A 2014-11-03 2015-11-03 Drug for inhibiting adipose cell differentiation and insulin resistance Pending CA3003760A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201410610777 2014-11-03
CN201410610777.X 2014-11-03
CN201510021469.8 2015-01-15
CN201510021469 2015-01-15
PCT/CN2015/093726 WO2016070798A1 (zh) 2014-11-03 2015-11-03 一种抑制脂肪细胞分化和胰岛素耐受的药物

Publications (1)

Publication Number Publication Date
CA3003760A1 true CA3003760A1 (en) 2016-05-12

Family

ID=55908589

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3003760A Pending CA3003760A1 (en) 2014-11-03 2015-11-03 Drug for inhibiting adipose cell differentiation and insulin resistance

Country Status (7)

Country Link
US (2) US20180015148A1 (cg-RX-API-DMAC7.html)
EP (1) EP3246043A4 (cg-RX-API-DMAC7.html)
JP (2) JP2018501195A (cg-RX-API-DMAC7.html)
CN (2) CN114558111A (cg-RX-API-DMAC7.html)
AU (1) AU2015342324B2 (cg-RX-API-DMAC7.html)
CA (1) CA3003760A1 (cg-RX-API-DMAC7.html)
WO (1) WO2016070798A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016127948A1 (zh) * 2015-02-13 2016-08-18 清华大学 一种重组蛋白质药物的分子设计
CN115721730B (zh) 2016-11-10 2025-03-14 北京普罗吉生物科技发展有限公司 聚乙二醇化血管内皮抑制素类似物及其应用
US10276161B2 (en) 2016-12-27 2019-04-30 Google Llc Contextual hotwords

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2307792C (en) * 1997-10-31 2007-06-26 Children's Medical Center Corporation Method for regulating size and growth of vascularized normal tissue
AU2002323543A1 (en) * 2001-09-07 2003-03-24 Board Of Regents, The University Of Texas System Compositions and methods of use of targeting peptides against placenta and adipose tissues
US7524811B2 (en) * 2003-08-29 2009-04-28 Children's Medical Center Corporation Anti-angiogenic peptides from the N-terminus of endostatin
CN101596320B (zh) * 2006-01-20 2013-01-09 清华大学 一种治疗肿瘤的药物及其应用
CN103083681A (zh) * 2006-01-20 2013-05-08 清华大学 一种治疗肿瘤的药物及其应用
BRPI0819434A2 (pt) * 2007-11-08 2019-09-24 Univ Utah Res Found método de tratamento ou prevenção de doenças hepáticas e uso de antagonistas á angiogênese em condições de proliferação venosa anormal
CN101219206A (zh) * 2008-02-01 2008-07-16 山东先声麦得津生物制药有限公司 重组人血管内皮抑制素在制药中的应用
CN102698270B (zh) * 2011-03-28 2016-02-03 清华大学 一种增强靶细胞摄取治疗剂的方法和药物组合物
AU2012236199A1 (en) * 2011-03-30 2013-09-26 Board Of Regents Of The University Of Texas System Methods and compositions for targeting adipose cells in mammals
RU2014113924A (ru) * 2011-09-09 2015-10-20 Тсинхуа Юниверсити Мутанты эндостатина с мутациями в сайтах связывания атф

Also Published As

Publication number Publication date
US20180015148A1 (en) 2018-01-18
WO2016070798A1 (zh) 2016-05-12
CN107148277A (zh) 2017-09-08
CN114558111A (zh) 2022-05-31
EP3246043A4 (en) 2018-09-05
JP7227197B2 (ja) 2023-02-21
EP3246043A1 (en) 2017-11-22
AU2015342324B2 (en) 2021-08-19
EP3246043A9 (en) 2018-03-14
JP2020172546A (ja) 2020-10-22
CN107148277B (zh) 2022-03-22
AU2015342324A1 (en) 2017-06-29
JP2018501195A (ja) 2018-01-18
US20220409703A1 (en) 2022-12-29

Similar Documents

Publication Publication Date Title
US20220409703A1 (en) Drug for inhibiting adipose cell differentiation and insulin resistance
JP6813155B2 (ja) 抗肥満及び抗糖尿作用を有するペプチド及びその用途
EP3189849B1 (en) Peptides for preventing or treating obesity
JP6875516B2 (ja) 抗肥満および抗糖尿病効能を有するペプチド、並びにその用途
CN111494605B (zh) Creg蛋白用于预防或治疗阿霉素心肌损伤的医药用途
WO2016197592A1 (zh) 一种长链非编码rna hnf1a-as1在制备治疗人体恶性实体瘤药物中的应用
Deane et al. Aquaporin 1a expression in gill, intestine, and kidney of the euryhaline silver sea bream
CN108004310B (zh) 肾素(原)受体(p)rr基因及其抑制剂的应用
Wang et al. Leptin gene protects against cold stress in Antarctic toothfish
CN119013405A (zh) 包含utr的核酸构建体及其应用
CN111808186B (zh) 一种人源性分泌型fndc5蛋白及其制备方法和用途
CN117100742B (zh) Rhodiolin在制备治疗人甲状腺乳头状癌药物中的应用
CN112680390B (zh) 重组微生物、其代谢物、及其用于治疗或/及预防脂肪肝及心血管疾病的用途
CN116904577A (zh) 一种Bdh1蛋白在糖尿病心脏保护中的应用及基因药物
CN120700131A (zh) Osgin2基因及其腺病毒的应用
HK1240832B (en) Peptides for preventing or treating obesity
JP2003089636A (ja) 熱ショック蛋白質の合成抑制及び機能抑制剤
CN103705523A (zh) 前列环素及类似物在体外抑制心肌成纤维细胞增殖的应用

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20201103

EEER Examination request

Effective date: 20201103

EEER Examination request

Effective date: 20201103

EEER Examination request

Effective date: 20201103

EEER Examination request

Effective date: 20201103